Samrat Pharmachem Limited announced its financial results for the quarter ended June 30, 2026, with the Board of Directors taking note of these unaudited standalone financial results at a meeting held on August 14, 2026. The company reported a profit after tax of ₹87.60 lakh on revenues of ₹7,976.10 lakh for the quarter. The Board Meeting commenced at 14:00 hours and concluded at 20:00 hours on Friday, August 14, 2026, with the attached Un-Audited Standalone Financial Results and the Limited Review Report of the Statutory Auditor considered and recorded during this meeting.
Samrat Pharmachem achieved a significant financial turnaround in the June 2026 quarter, reporting a standalone net profit of ₹87.60 lakh compared to a net loss of ₹22.9 lakh in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a complete reversal of the company's financial performance from the same period last year, with the latest figures showing even stronger profitability metrics. The company has demonstrated remarkable improvement in its financial health, moving from substantial losses to positive earnings in just one quarter.
The company's sales revenue increased by 5.43% to ₹7,976.10 lakh in Q1 FY27, up from ₹75.65 crore recorded in the June 2025 quarter. As reported by Business Standard, this revenue growth demonstrates the company's ability to expand its business operations despite challenging market conditions, with the latest figures showing consistent revenue momentum. The company's revenue trajectory shows steady growth over the past year, indicating effective business expansion strategies.
The company reported basic and diluted earnings per equity share of ₹2.84 for the quarter ended June 30, 2026. The company's operating profit margin (OPM) improved to 1.13% in the June 2026 quarter compared to 0.17% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this improvement in profitability metrics indicates enhanced operational efficiency and better cost management during the quarter. The strong earnings per share performance reflects the company's improved operational leverage and profitability enhancement strategies.
PBDT (Profit Before Depreciation and Tax) surged by 368% to ₹1.78 crore in Q1 FY27 from ₹0.38 crore in the same quarter last year. As reported by Business Standard, PBT (Profit Before Tax) increased by 657% to ₹1.59 crore compared to ₹0.21 crore in the June 2025 quarter, reflecting the company's strong operational performance during the quarter. The latest results show even stronger performance across all profitability metrics, demonstrating the company's improved financial health and operational efficiency. The company's PBDT margin improved significantly from the previous year, indicating better cost management and operational efficiency.
